China Neurovascular Devices Market, By Region, By Competition, Opportunities & Forecast, 2020-2030F

The China Neurovascular Devices Market was valued at USD 255.56 Million in 2024, and is expected to reach USD 392.01 Million by 2030, rising at a CAGR of 7.35%. The China Neurovascular Devices Market is undergoing a strategic inflection point, shaped by a surge in stroke-related cases, evolving clinical practices, and accelerated adoption of advanced intervention technologies. The rising burden of ischemic and hemorrhagic strokes particularly among the country’s aging population is driving increased demand for high-precision neurovascular devices across a widening spectrum of hospitals, from top-tier urban centers to emerging regional facilities.

China is positioning itself as a critical growth engine for neurovascular device manufacturers, underpinned by a favorable policy environment, expanding reimbursement access, and a deliberate national push to build a self-reliant medtech ecosystem. Market participants that localize product offerings, align with government-supported stroke care models, and invest in physician training and regional deployment strategies are likely to gain competitive traction and unlock scalable, long-term value in this rapidly evolving landscape.

Key Market Drivers

Rising Stroke Prevalence and Aging Population

The rising incidence of stroke, combined with China’s rapidly aging population, is acting as a powerful long-term catalyst for the growth of the China Neurovascular Devices Market. This demographic and disease burden convergence is not only expanding the clinical need for advanced intervention tools but also reshaping how hospitals, policymakers, and manufacturers approach neurovascular care. China is undergoing a pronounced demographic transition, with individuals aged 60 and above accounting for more than 20% of the total population by the end of 2023. Projections indicate this segment will surpass 30% by 2035, reflecting a structural shift toward a senior-dominated population.

This aging trend is expected to exert substantial pressure on the healthcare system, particularly in areas like neurovascular care, where age-related cerebrovascular conditions are most prevalent and resource-intensive. Age-related vascular degeneration, hypertension, diabetes, and sedentary lifestyles are significantly increasing stroke susceptibility. Ischemic stroke alone accounts for over 70% of total stroke cases in China, most commonly affecting those aged 60+. This expanding elderly population directly increases the volume of patients requiring interventional therapies such as mechanical thrombectomy, aneurysm coiling, and flow diversion procedures, thereby driving consistent demand for neurovascular devices.

China faces one of the heaviest stroke burdens globally, recording over 3 million new stroke cases each year and managing a population of more than 13 million stroke survivors in need of continuous care and rehabilitation. This epidemiological landscape positions China as a critical focal point for stroke management, underscoring an urgent demand for scalable, high-impact prevention frameworks and advanced interventional treatment solutions to reduce long-term disability and healthcare system strain. Tertiary hospitals and designated stroke centers are reporting a notable rise in acute stroke interventions, particularly within the critical 6-hour treatment window.

Mechanical thrombectomy procedures, once limited to top-tier facilities, are now expanding into regional and county-level hospitals. This uptick in procedural throughput is contributing directly to higher device adoption across a broadening range of institutions. China’s central and provincial governments have identified stroke as a national health priority due to its economic burden and public health impact.

Stroke accounts for the highest rate of disability-adjusted life years (DALYs) in the country, creating long-term financial pressure on families and the healthcare system. Expanded insurance coverage for stroke-related interventions. Supported the establishment of certified stroke centers with the capacity to perform neurointerventional procedures. Encouraged adoption of cost-effective technologies that can reduce disability rates in the aging population. These policies have created a strong reimbursement and infrastructure framework that encourages hospitals to invest in neurovascular equipment and training.

Key Market Challenges

Uneven Access to Neurointerventional Care Across Regions

China’s healthcare delivery is highly centralized in urban Tier I cities, such as Beijing, Shanghai, and Guangzhou. In contrast, rural and lower-tier cities often lack the necessary infrastructure, trained specialists, and funding to offer advanced neurovascular procedures.

Limits device utilization in underdeveloped regions. Creates regional disparities in procedure volumes and treatment outcomes. Delays national scalability for device manufacturers seeking uniform penetration. Shortage of neurointerventionists in secondary hospitals. Insufficient investment in high-end imaging systems and DSA labs. Inconsistent implementation of government policies across provinces.

Key Market Trends

Rise of Smart Neurovascular Devices Integrated with AI and Robotics

China is rapidly embracing digital transformation in neurovascular care, with increasing integration of AI-powered imaging platforms, robotic-assisted interventions, and real-time data analytics in endovascular procedures.

AI algorithms are being developed to aid in early stroke detection, automated clot localization, and treatment planning, significantly reducing time-to-intervention. Robotic-assisted systems offer greater precision, especially in complex navigation through cerebral vessels, and are expected to gain ground in high-volume stroke centers. Domestic medtech start-ups and research institutions are collaborating to localize AI solutions specifically tailored for the Chinese population and hospital workflows. Companies that integrate intelligent capabilities into device platforms, such as smart coils or AI-guided thrombectomy systems, will be well-positioned to gain market share and differentiate in an increasingly tech-driven landscape.

Key Market Players

Zylox-Tonbridge
MicroPort Scientific Corporation
Medtronic
Terumo (China) Holdings Co., Ltd.
Integra LifeSciences Holdings Corporation
Genesis MedTech
ACANDIS GmbH
Stryker

Report Scope:

In this report, the China Neurovascular Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

China Neurovascular Devices Market, By Device:

Cerebral Embolization and Aneurysm Coiling Devices
Cerebral Angioplasty and Stenting Systems
Neurothrombectomy Devices
Support Devices
Trans Radial Access Devices

China Neurovascular Devices Market, By Therapeutic Application:

Stroke
Cerebral Artery
Cerebral Aneurysm
Others

China Neurovascular Devices Market, By End User:

Hospitals
Specialty Clinics
Others